Table 2 General characteristics of population
Population N = 99 | Afatinib N = 40 | Erlotinib N = 26 | Gefitinib N = 33 | |
|---|---|---|---|---|
Gender | ||||
▪ Women | 73 (73.7%) | 28 (70.0%) | 22 (84.6%) | 23 (69.7%) |
▪ Men | 26 (26.3%) | 12 (30.0%) | 4 (15.4%) | 10 (30.3%) |
Age (years) | 61.2 (14.0) | 57.925 (14.5) | 64.3 (12.8) | 62.8 (14.0) |
Stage IV NSCLC | 83 (83.8) | 33 (82.5) | 22 (84.61) | 28 (84.84) |
Current or former smoker | 22 (22.2%) | 3 (11.5%) | 4 (12.1%) | 15 (15.2%) |
Woodsmoke exposure | 16 (16.2%) | 4 (15.4%) | 6 (18.2%) | 16 (16.2%) |
Karnofsky | ||||
• 50 | 2 (2.2%) | 1 (2.6%) | 1 (4.2%) | 0 (0.0%) |
• 60 | 3 (3.2%) | 2 (5.3%) | 0 (0.0%) | 1 (3.2%) |
• 70 | 12 (12.9%) | 4 (10.5%) | 4 (16.7%) | 4 (12.9%) |
• 80 | 33 (35.5%) | 14 (36.8%) | 7 (29.2%) | 12 (38.7%) |
• 90 | 38 (40.9%) | 16 (42.1%) | 12 (50%) | 10 (32.3%) |
• 100 | 5 (5.4%) | 1 (2.6%) | 0 (0.0%) | 4 (12.9%) |
• Not Reported | 6 | 2 | 2 | 2 |
ECOG | ||||
• 0 | 2 (2.2%) | 0 (0.0%) | 0 (0.0%) | 2 (6.5%) |
• 1 | 75 (81.5%) | 34 (91.9%) | 18 (75.0%) | 23 (74.2%) |
• 2 | 12 (13.0%) | 2 (5.4%) | 4 (16.7%) | 6 (19.4%) |
• 3 | 3 (3.3%) | 1 (2.7%) | 2 (8.3%) | 0 (0.0%) |
• Not Reported | 7 | 3 | 2 | 2 |
Diabetes Mellitus | 17 (17.2%) | 5 (12.5%) | 5 (19.2%) | 7 (21.2%) |
Arterial hypertension | 23 (23.2%) | 8 (20.0%) | 7 (26.9%) | 8 (24.2%) |
EGFR Mutation | ||||
▪ EGFR del 19 | 25 (25.3%) | 12 (30.0%) | 5 (19.2%) | 8 (24.2%) |
▪ EGFR L858R | 67 (67.7%) | 27 (67.5%) | 16 (61.5%) | 24 (72.7%) |
▪ Non-reported | 7 (7.1% | 1 (2.5%) | 5 (19.2%) | 1 (3.0%) |